PUNE: At a time when all norms are calling for cautious use of antivirals and antibacterials against Covid, experts, including those from the national Covid task force, are becoming increasingly concerned about the heavy use of molnupiravir and azithromycin by doctors, including general practitioners, treating those with mild illness.
Experts said paracetamol and other supportive care is good enough to recover from mild disease.
Only those Covid patients who are unvaccinated and those with underlying medical conditions can be considered high-risk patients. They need to be monitored for progression towards severe symptoms and can be treated cautiously with the antiviral molnupiravir, the experts said.
"Molnupiravir is currently not recommended for management of mild illness due to modest benefit in an unvaccinated population," said infectious diseases expert Sanjay Pujari, a member of the national Covid task force.
Despite norms that say the drug should not be used in mild Covid patients without any underlying risk factors, it is still being widely prescribed to treat mild illness, Pujari said.